The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Long-Term Use of Bisphosphonates in Osteoporosis
Abstract
CONTEXT: Bisphosphonates have been widely used in the treatment of osteoporosis. Uncommon side effects have emerged in postapproval use. Because bisphosphonates accumulate in bone and are released for months or years after treatment is stopped, it is reasonable to consider the clinical question of how long to treat. OBJECTIVE: In this personal perspective, we review the pharmacology and mechanism of action of bisphosphonates and the clinical studies that support their efficacy. We then review the literature for longer-term studies and reports of possible side effects that were not seen in clinical trials. RESULTS: Bisphosphonates have demonstrated antifracture efficacy in randomized, placebo-controlled trials of 3 and 4 yr duration and have been widely used since the initial release of alendronate in 1995. For zoledronic acid and risedronate, an early effect (fractures reduced within 6-12 months of starting therapy) has been shown. A sustained effect for risedronate has been shown through 5 yr and suggested through 7 yr. Ten-year data with alendronate and 8 yr data with risedronate indicated good tolerability and safety; it is unlikely that longer-term studies will be done. Side effects that emerged in clinical trials include esophageal irritation with oral administration and acute phase response with iv treatment or high-dose oral therapy. Uncommon side effects that have been noted with wide clinical use include osteonecrosis of the jaw, musculoskeletal complaints, and atypical fractures. The numbers of events are small, and a clear cause-and-effect relationship between these events and bisphosphonate treatment has not been established. Because bisphosphonates accumulate in bone, they create a reservoir leading to continued release from bone for months or years after treatment is stopped. Studies with risedronate and alendronate suggest that if treatment is stopped after 3-5 yr, there is persisting antifracture efficacy, at least for 1-2 yr. CONCLUSIONS: Bisphosphonates are popular and effective for treatment of osteoporosis. Because they accumulate in bone and provide some residual antifracture reduction when treatment is stopped, we recommend a drug holiday after 5-10 yr of bisphosphonate treatment. The duration of treatment and length of the holiday are based on fracture risk and pharmacokinetics of the bisphosphonate used. Patients at mild risk might stop treatment after 5 yr and remain off as long as bone mineral density is stable and no fractures occur. Higher risk patients should be treated for 10 yr, have a holiday of no more than a year or two, and perhaps be on a nonbisphosphonate treatment during that time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003 · cited 1×
“No increase in the rate of AF was noted in the HORIZON Recurrent Fracture Trial, a smaller and shorter study, in which careful evaluation of AF and its serious adverse events was performed, (30), nor was an increase in AF noted in the oncology trials of zoledronic acid, using a dose approximately 10 times higher than…”
BackgroundEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650 · cited 3×
“ONJ is defined as exposed necrotic bone in the maxillofacial region, not healing after 6–8 wk, in patients with no history of craniofacial radiation (16).”
BackgroundMethodInfluentialSelf-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Self-citationBlack, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
(2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.11.003 · Cited by 837
Mashiba, T., Hirano, T., Turner, C. H., Forwood, M. R., Johnston, C. C., & Burr, D. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.613 · Cited by 688
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Pols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593
Low-Energy Femoral Shaft Fractures Associated With Alendronate Use
Neviaser, A. S., Lane, J. M., Lenart, B. A., Edobor-Osula, F., & Lorich, D. G. (2008) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e318172841c · Cited by 526
Subtrochanteric insufficiency fractures in patients on alendronate therapy: A CAUTION
Goh, S.-K., Yang, K. Y., Koh, J. S. B., Wong, M. K., Chua, S. Y., Chua, D. T. C., & Howe, T. S. (2007) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.89b3.18146 · Cited by 513
Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate
Lenart, B. A., Lorich, D. G., & Lane, J. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707493 · Cited by 498
Adverse effects of bisphosphonates: Implications for osteoporosis management
Kennel, K. A., & Drake, M. T. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60752-0 · Cited by 496
Kwek, E. B. K., Goh, S. K., Koh, J. S. B., Png, M. A., & Howe, T. S. (2008) · Injury · doi:10.1016/j.injury.2007.08.036 · Cited by 445
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
Lenart, B. A., Neviaser, A. S., Lyman, S., Chang, C. C., Edobor-Osula, F., Steele, B., van der Meulen, M. C. H., Lorich, D. G., & Lane, J. M. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0805-x · Cited by 384
Abrahamsen, B., Eiken, P., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081247 · Cited by 366
The acute-phase response after bisphosphonate administration
Adami, S., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., & Lo Cascio, V. (1987) · Calcified Tissue International · doi:10.1007/bf02556671 · Cited by 357
Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis
Mellström, D. D., Sörensen, O. H., Goemaere, S., Roux, C., Johnson, T. D., & Chines, A. A. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0286-7 · Cited by 350
Miller, P. D., Roux, C., Boonen, S., Barton, I. P., Dunlap, L. E., & Burgio, D. E. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050817 · Cited by 318
Jamal, S. A., Bauer, D. C., Ensrud, K. E., Cauley, J. A., Hochberg, M., Ishani, A., & Cummings, S. R. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070112 · Cited by 301
Schwartz, A. V., Bauer, D. C., Cummings, S. R., Cauley, J. A., Ensrud, K. E., Palermo, L., Wallace, R. B., Hochberg, M. C., Feldstein, A. C., Lombardi, A., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.11 · Cited by 289
Severely Suppressed Bone Turnover and Atypical Skeletal Fragility
Visekruna, M., Wilson, D., & McKiernan, F. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2803 · Cited by 270
Osteonecrosis of the Jaw — Do Bisphosphonates Pose a Risk?
Bilezikian, J. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068157 · Cited by 268
Capeci, C. M., & Tejwani, N. C. (2009) · The Journal of Bone & Joint Surgery · doi:10.2106/jbjs.h.01774 · Cited by 252
Molecular mechanisms of action of bisphosphonates
Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., M̈onkk̈onen, J., Auriola, S., Chilton, K. M., & Russell, R. G. G. (1999) · Bone · doi:10.1016/s8756-3282(99)00070-8 · Cited by 237
Fracture risk remains reduced one year after discontinuation of risedronate
Watts, N. B., Chines, A., Olszynski, W. P., McKeever, C. D., McClung, M. R., Zhou, X., & Grauer, A. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0460-7 · Cited by 237
Self-citationAlendronate and Atrial Fibrillation
Cummings, S. R., Schwartz, A. V., & Black, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmc076132 · Cited by 230
Prolonged bisphosphonate release after treatment in children
Papapoulos, S. E., & Cremers, S. C. L. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmc062792 · Cited by 210 · cited 1×
“It is a reasonable question when considering bisphosphonate therapy, however, because these drugs accumulate in the skeleton, leading to a reservoir that continues to be released for months or years after treatment is stopped (83).”
BackgroundUse of Alendronate and Risk of Incident Atrial Fibrillation in Women
Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., & Psaty, B. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.826 · Cited by 199
Reports of Esophageal Cancer with Oral Bisphosphonate Use
Wysowski, D. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808738 · Cited by 198
Unusual mid‐shaft fractures during long‐term bisphosphonate therapy
Odvina, C. V., Levy, S., Rao, S., Zerwekh, J. E., & Rao, D. S. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03581.x · Cited by 186
Sørensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D., Cummings, S. R., & Baron, J. A. (2008) · BMJ · doi:10.1136/bmj.39507.551644.be · Cited by 178
Comparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy
Zojer, N., Keck, A. V., & Pecherstorfer, M. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00004 · Cited by 167
(2008) · PubMed · Cited by 160
Bone safety of long-term bisphosphonate treatment
Rodan, G. A., Reszka, A. A., Golub, E. E., & Rizzoli, R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004475 · Cited by 139
Armamento‐Villareal, R., Napoli, N., Diemer, K., Watkins, M. P., Civitelli, R., Teitelbaum, S. L., & Novack, D. V. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9263-5 · Cited by 131
Bisphosphonates and Atrial Fibrillation: Systematic Review and Meta-Analysis
Loke, Y. K., Jeevanantham, V., & Singh, S. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00004 · Cited by 128
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Boonen, S., Sellmeyer, D. E., Lippuner, K., Orlov-Morozov, A., Abrams, K. B., Mesenbrink, P. G., Eriksen, E. F., & Miller, P. D. (2008) · Kidney International · doi:10.1038/ki.2008.193 · Cited by 127
Atrial fibrillation in fracture patients treated with oral bisphosphonates
Abrahamsen, B., Eiken, P., & Brixen, K. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02065.x · Cited by 117
Schneider, J. P. (2006) · PubMed · Cited by 110
Safety of Bisphosphonates in the Treatment of Osteoporosis
Recker, R. R., Lewiecki, E. M., Miller, P. D., & Reiffel, J. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.004 · Cited by 106
Bisphosphonate-Induced Hypocalcemia: Report of 3 Cases and Review of Literature
Maalouf, N. M., Heller, H. J., Odvina, C. V., Kim, P. J., & Sakhaee, K. (2006) · Endocrine Practice · doi:10.4158/ep.12.1.48 · Cited by 105
Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis
Armamento‐Villareal, R., Napoli, N., Panwar, V., & Novack, D. V. (2006) · New England Journal of Medicine · doi:10.1056/nejmc062268 · Cited by 104
Koo, S., Kucher, N., Fanikos, J., & Goldhaber, S. Z. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.346-b · Cited by 103
Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis
Scott, D. L., Kingsley, M., & Ch, B. (2006) · Cited by 91
Yearly zoledronic acid in postmenopausal osteoporosis.
Karam, R., Camm, A. J., & McClung, M. R. (2007) · PubMed · Cited by 87
More on Reports of Esophageal Cancer with Oral Bisphosphonate Use
Abrahamsen, B., Eiken, P., & Eastell, R. (2009) · New England Journal of Medicine · doi:10.1056/nejmc096026 · Cited by 85
Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation
Bunch, T. J., Anderson, J. L., May, H. T., Muhlestein, J. B., Horne, B. D., Crandall, B. G., Weiss, J. P., LAPPE, D. L., Osborn, J. S., & Day, J. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.037 · Cited by 80
Is There a Role for Bisphosphonates in Chronic Kidney Disease?
Miller, P. D. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00271.x · Cited by 75
Treatment of osteoporosis in chronic kidney disease and end-stage renal disease
Miller, P. D. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0021-y · Cited by 74
The Role of Bone Biopsy in Patients with Chronic Renal Failure
Miller, P. D. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02430508 · Cited by 73
Alendronate-associated esophagitis: endoscopic and pathologic features
Ribeiro, A. C., DeVault, K. R., Wolfe, J. T., & Stark, M. E. (1998) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(98)70256-1 · Cited by 71
Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis
HAWORTH, C. S., Selby, P. L., Webb, A. K., Mawer, E. B., Adams, J. E., & Freemont, A. J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79826-3 · Cited by 69
Grosso, A., Douglas, I., Hingorani, A. D., MacAllister, R. J., & Smeeth, L. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004720 · Cited by 68
Osteoporosis treatments and adverse events
Solomon, D. H., Rekedal, L., & Cadarette, S. M. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832ca433 · Cited by 63
More on Atypical Fractures of the Femoral Diaphysis
Kwek, E. B. K., Koh, J. S. B., & Howe, T. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc080861 · Cited by 62
Yearly Zoledronic Acid in Postmenopausal Osteoporosis
de Nijs, R. N. J., & Westgeest, A. A. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071514 · Cited by 62
Diagnosis and Treatment of Osteoporosis in Chronic Renal Disease
Miller, P. D. (2009) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2009.01.007 · Cited by 61
Lee, P., der Wall, H. V., & Seibel, M. J. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03346353 · Cited by 59
Renal safety of intravenous bisphosphonates in the treatment of osteoporosis
Lewiecki, E. M., & Miller, P. D. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.663 · Cited by 46
Imai, K., Yamamoto, S., Anamizu, Y., & Horiuchi, T. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0771-y · Cited by 45
Bisphosphonate-Associated Osteonecrosis of the Jaw
Treister, N. S., & Woo, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmicm055784 · Cited by 37
More on atypical fractures of the femoral diaphysis.
Lee, P., & Seibel, M. J. (2008) · PubMed · Cited by 37
Miller, P. D., Ward, P., Pfister, T., Leigh, C., & Body, J. (2008) · PubMed · Cited by 17
Bisphosphonate Treatment for Osteoporosis
Watts, N. B. (2000) · Elsevier eBooks · doi:10.1016/b978-012068705-3/50009-7 · Cited by 8
Self-citation
Cited by
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Watts, N. B., Adler, R. A., Bilezikian, J. P., Drake, M. T., Eastell, R., Orwoll, E. S., & Finkelstein, J. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3045 · Cited by 611
Self-citationStröm, O., Borgström, F., Kanis, J. A., Compston, J., Cooper, C., McCloskey, E. V., & Jönsson, B. (2011) · Archives of Osteoporosis · doi:10.1007/s11657-011-0060-1 · Cited by 546
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pollack, R. P., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.s3.1 · Cited by 441
Self-citationNCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Metadata
- Authors
- Watts, N. B., & Diab, D. L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-04-01
- Volume
- 95
- Issue
- 4
- Pages
- 1555-1565
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2160145148
- Cited by
- 542
- References
- 78
- FWCI
- 58.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.